Individual Differences in Working Memory Capacity Predict Topiramate-Related Cognitive Deficits

Barkley, Christopher M.; Hu, Zhenhong; Fieberg, Ann; Eberly, Lynn E.; Leppik, Ilo E.; Marino, Susan E.

doi:10.1097/jcp.0000000000000949

Cited by 6 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Severity of Topiramate‐Related Working Memory Impairment Is Modulated by Plasma Concentration and Working Memory Capacity

Callisto

Illamola

Barkley

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Drug side effects that impair cognition can lead to diminished quality of life and discontinuation of therapy. Topiramate is an antiepileptic drug that elicits cognitive deficits more frequently than other antiepileptic drugs, impairing multiple cognitive domains including language, attention, and memory. Although up to 40% of individuals taking topiramate may experience cognitive deficits, we are currently unable to predict which individuals will be most severely affected before administration. The objective of this study was to show the contributions of plasma concentration and working memory capacity in determining the severity of an individual's topiramate‐related cognitive impairment. Subjects were enrolled in a double‐blind, placebo‐controlled crossover study during which they received a single dose of either 100, 150, or 200 mg topiramate. Working memory function was assessed using a modified Sternberg working memory task with 3 memory loads administered 4 hours after dosing. After adjustment for differences in working memory capacity, each 1 μg/mL of topiramate plasma concentration was associated with a 3.6% decrease in accuracy for all memory loads. Placebo effects occurred as a function of working memory capacity, with individuals with high working memory capacity experiencing less severe placebo‐related impairment compared with those with low working memory capacity. Our results demonstrate that severity of topiramate‐related cognitive deficits occurs as a function of both drug exposure and baseline cognitive function. By identifying patient‐ and exposure‐related characteristics that modulate the severity of cognitive side effects, topiramate dosing strategies may be individually tailored in the future to prevent unwanted cognitive impairment.

show abstract